Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-025 in Severe to Critical COVID-19 with ARDS
NCT04750278Phase 3Terminated
- Sponsor
- Foresee Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aderamastat in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Foresee Pharmaceuticals. Primary endpoint: Percentage of Patients Alive and Not Requiring Non-invasive or Invasive Ventilation at Day 28. Started Apr 2021; status: terminated.
02
Drugs
aderamastat
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04750278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750278.